


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-10. (Canceled)

11. (Currently amended) A compound of ~~general the~~  
formula-(I):



(I)

and pharmaceutically acceptable salts or prodrugs thereof, wherein:

n is 0, 1 or 2;

R<sup>1</sup> and R<sup>2</sup>, independently of each other, are H, OH or OCH<sub>3</sub>;

R<sup>3</sup> is H or CH<sub>3</sub>;

R<sup>4</sup> is H, C<sub>1</sub>-C<sub>3</sub> straight or branched alkyl or, together with R<sup>3</sup>, forms a five to seven-membered carbocyclic ring;

and R<sup>5</sup> and R<sup>6</sup>, independently of each other, are H or C<sub>1</sub>-C<sub>5</sub> straight or branched alkyl

with the provisos that:

$R^1$  and  $R^2$  cannot be both hydrogen;

when  $n$  is 0,  $R^1$  and  $R^2$  are both hydroxyl, and  $R^3$  and  $R^5$  are hydrogen,  $R^4$  cannot be  $CH_3$ ;

when  $n$  is 0,  $R^3$  is H and  $R^4$  is H or  $CH_3$ ,  $R^6$  cannot be  $C_1$ - $C_3$  straight or branched alkyl;

and that the ~~compounds~~ compound cannot be:

- 1-(4-hydroxyphenyl)-2-hydroxylaminoethane,
- 1-(4-hydroxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-4-hydroxylaminobutane
- 1-(3-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminoethane,
- N-methyl-1-(3,4-dihydroxyphenyl)-2-hydroxylaminopropane,
- 1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane,
- N-methyl-1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane, or
- N-methyl-1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane.

**12. (Currently amended)** A-The compound according to claim 11, which is selected from the group consisting of:

- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;

- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-propyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-methyl-hydroxylamine;
- N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3,4-dihydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-methyl-hydroxylamine;

- N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-hydroxylamine;
- N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-methyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-hydroxylamine;

- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;
  - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-hydroxylamine;
  - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
  - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-methyl-hydroxylamine;
  - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-hydroxylamine;
  - N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;
- and the pharmaceutically acceptable salts thereof.

**13. (Currently amended)** ~~Pharmaceutical compositions~~  
~~containing~~ A pharmaceutical composition comprising one or more  
compounds ~~of formula (I)~~ according to claim 11 in a mixture with  
suitable excipients and/or carriers.

**14. (Currently amended)** ~~Pharmaceutical compositions~~  
~~containing~~ A pharmaceutical composition comprising one or more  
compounds ~~of formula (I)~~ according to claim 11 and a compound for  
the treatment of central and peripheral nervous system disorders  
involving protein misfolding and/or misaggregation of beta-  
amyloid peptide, alpha-synuclein, prion protein and huntingtin  
selected from Alzheimer's Disease, Lewy body disease, Parkinson's  
Disease, spongiform encephalopathies, Huntington's Disease and

systemic AA amyloidosis, in admixture with suitable excipients  
and/or carriers.